EpiVax Congratulates Dr. Leslie Cousens! Scientific Director of Protein Therapeutics and Lead Scientist of the Tregitope project at EpiVax, Dr. Leslie Cousens is one of five RI Bioscience Award winners for 2013! “The Tech Collective’s Rhode Island Bioscience Awards honor those who are innovating and impacting our industry. These are the scientists, researchers, thinkers, and culture ...

Full Article Here For their extraordinary professional achievements and outstanding service to their communities, five Smith College alumnae have been named 2013 recipients of the prestigious Smith College Medal. The honor was bestowed today, Thursday February 21st at the Annual Rally Day at Smith College. EpiVax congratulates Dr. Annie De Groot on her award and many achievements!

EpiVax says Novozymes Collaboration has $3bn Potential by: Gareth Macdonald EpiVax says combining its immune ‘off switch’ drugs with Novozymes’ half-life boosting Albufuse platform could deliver a $3bn (€2.2bn) section of the autoimmune disease market. Full Article in in-Pharma Technologist.com – https://bit.ly/EpiVaxNZinterPR  

EpiVax-Novozymes Tregitope-Albumin Fusion Moves ‘Paradigm-Shifting’ Treatment for Diabetes Closer to Clinical Trials Full Article – https://bit.ly/EpiVaxNovoPR Providence, RI – EpiVax, Inc. is pleased to announce a new Collaborative Research Agreement with Novozymes Biopharma. The collaboration will enable EpiVax to rapidly advance its Tregitope immune-modulating technology as a potential treatment for autoimmune diseases. When used as a buffering ...

EpiVax is featured in the February issue of RI Medical Journal (RIMJ)! EpiVax Article Here! iCubed, the academic partner of EpiVax, was in the news recently, for co-coordinating an important series on biotechnology in RI. Denice Spero, the Co-Director of the recently established Institute for Immunology and Informatics (iCubed) wrote the introductory article “Showcasing Bioscience in Rhode Island.” EpiVax is featured ...

We were recently contacted by researchers at the Pasteur Institute of Beijing (Ruichen Wei, Qiben Leng) who were grappling with an out break of Hand-Foot-Mouth Disease, a serious infection caused by enterovirus 71 (EV71) among other viruses. They were interested identifying T cell epitopes, so as to begin to develop an epitope-based vaccine. We applied ...

Dr. Annie De Groot, CEO/CSO of EpiVax Inc., will be a keynote speaker at the inaugural Immunogenicity and Immunotoxicity Conference, one of four parallel tracks to the 2nd Novel Immunotherapeutics Summit on January 31 – February 1, 2013 in San Diego, CA. The conference brings together leading experts in industry, academia and the FDA. The ...

Title: Conservation of HIV-1 T cell epitopes across time and clades: Validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine Link: https://www.sciencedirect.com/science/article/pii/S0264410X12014880 Congratulations EpiVax on another top-notch publication!

See our Recent Press Releases for 2012! November 1 2012 EpiVax CIDP PR01Nov2012 August 30 2012 EpiVax Myozyme PR 30Aug2012 April 10 2012 EpiVax_Tregitope_10April2012 Contact us with any questions HERE

Providence, RI – Providence-based biotech company EpiVax, Inc. was awarded a new $55,000 grant from the GBS-CIDP Foundation International, to explore using Tregitopes as a novel immuno-modulator therapy for a nerve disease that is currently treated with intravenous immunoglobulin G (IVIG). This award and the recent addition of an SBIR grant for $600,000 to explore ...

Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease New paper on Tregitopes Published: DOI: https://dx.doi.org/10.4161/hv.21405 Authored by Leslie Cousens, Federico Mignozzi, Sander van der Marel, Yan Su, Richard Garman, Valerie Ferreira, William Martin, David W. Scott and Anne S. De Groot Babies born with Pompe disease require life-long treatment with enzyme-replacement therapy (ERT). Despite the ...

Bioterror is the real threat. At the most recent joint US-Korea wargames, held on the border of North and South Korea, biowarfare was one of the threats introduced, to which allied forces had little to no defense. That exercise drove home the importance of biowarfare preparedness, and the military is currently scrambling to get up ...

EpiVax is attending the Immunogenicity Summit in Bethesda this week. Look for Leslie and Annie in person (Annie is usually at the microphone asking questions about HLA associations). We will be piloting some new slides on Epitope Networks. (For more on that, see the link to our CHO/Host Cell protein talk, which is also available ...

Our Tregitope tour continues this month and on through the fall including stops in Orlando, Bethesda and Yokohama. Take a look at the list below and let us know if you’d like us to visit you while we’re in the area. ICIW 2012 Tutorial Session 10/7 – 10/10 In conjunction with: ACM International Conference on Bioinformatics and Computational ...

EpiVax Grant for treatment of Pompe Disease brings SBIR infusion to $3.4M for Proof of Principle Studies  Providence, RI – Providence-based biotech EpiVax, Inc. was awarded a new NIH SBIR Phase II grant totaling $300,000 in funding from the National Institutes of Health (NIH) NIAID for the first year of a two year program to application of Tregitope to Pompe ...